- Home
- IEX vs BBIO Comparison
IEX vs BBIO Comparison
Compare IEX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IEX | BBIO |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 12.7B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IEX | BBIO |
|---|---|---|
| Price | $215.36 | $67.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 25 |
| Target Price | ★ $229.63 | $86.33 |
| AVG Volume (30 Days) | 519.1K | ★ 2.8M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $3,457,500,000.00 | $502,076,000.00 |
| Revenue This Year | $4.09 | $89.45 |
| Revenue Next Year | $4.36 | $73.78 |
| P/E Ratio | $134.38 | ★ N/A |
| Revenue Growth | 5.77 | ★ 126.26 |
| 52 Week Low | $157.25 | $38.57 |
| 52 Week High | $223.85 | $84.94 |
Technical Indicators
Market Signals| Indicator | IEX | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 46.98 |
| Support Level | $204.03 | $62.37 |
| Resistance Level | $217.16 | $69.85 |
| Average True Range (ATR) | 3.88 | 2.77 |
| MACD | 0.37 | 0.10 |
| Stochastic Oscillator | 80.31 | 46.43 |
Price Performance
Historical ComparisonAbout IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. The company generated $3.5 billion in revenue in 2025.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.